Length 
126 pages

Date published 
July 2008

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 



Cancer Biomarkers Report Table of Contents

 

Cancer Biomarkers: Adoption Is Driving Growth

Author: John Bates, PhD

Chapter 1
BACKGROUND
1.1. Cancer Staging
1.2. AACR/FDA/NCI Collaborative
1.3. Cancer Biomarkers
1.4. Genetics
1.5. Research Areas
1.6. Treatment Selection
1.7. New Biomarkers
1.8. Circulating Tumor Cells
1.9. Cancer Stem Cells
1.10. Classification

Chapter 2
THE DISCOVERY OF CANCER BIOMARKERS
2.1. Genetic Methods
  DNA Arrays
  Southern Blot
  Polymerase Chain Reaction (PCR)
  Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
  Fluorescent In Situ Hybridization (FISH)
2.2. Protein Methods
  Immunohistochemistry
  Mass Spectrometry
2.3. Metabolomics
2.4. Imaging

  Imaging Techniques
  Positron Emission Tomography (PET)
  Computed Tomography (CT)
  Magnetic Resonance Spectroscopy (MRS)
  Magnetic Resonance Imaging (MRI)
  Single-Photon Emission Computed Tomography (SPECT)
  Ultrasound
  X-ray
  Biophotonics

Chapter 3
IMPORTANT CANCER BIOMARKERS
3.1. Lung Cancer
  Proteins
  Genes and Gene Arrays
  Splice Variants (Ciz1)
  Serum L-Lactate Dehydrogenase
  Telomerase
3.2. Colorectal Cancer
  Early Detection
  Proteins by SELDI
  Fecal DNA
  Genes and Epigenetic Markers
  Carcinoembryonic Antigen
3.3. Prostate Cancer
  Prostate-Specific Antigen (PSA)
  TIMP1
  MUC1
  B7-H3
  Genetic Biomarkers
  Epigenetic Alterations
3.4. Breast Cancer
  Growth Factors and Receptors
  Genetic Markers
3.5. Ovarian Cancer
  CA125
  Lysophospholipids
  H4
  Mammaglobin-2
3.6. Pancreatic Cancer
  CA19-9
  Blood Proteins
  MUC1
3.7. Liver Cancer
3.8. Leukemia
3.9. Other Cancers
3.10. Outlook for the Use of Cancer Biomarkers

Chapter 4
COMMERCIAL MARKETS
4.1. Commercial Importance of Biomarkers
  Competitive Opportunities
  Cost Saving
4.2. Market Considerations
  Economic Importance
  Companies

Chapter 5
SWOT ANALYSIS
5.1. Strengths
  Patients
  Healthcare Payers/Reimbursers
  Healthcare Providers
  Diagnostic/Drug Development Companies
5.2. Weaknesses
5.3. Opportunities
  Patients
  Healthcare Payers/Reimbursers
  Healthcare Providers
  Diagnostic/Drug Development Companies
5.4. Threats

Chapter 6
INSIGHT PHARMA REPORTS CANCER BIOMARKERS SURVEY—FEBRUARY 2008

Chapter 7
INTERVIEWS WITH CANCER BIOMARKER EXPERTS
7.1. Mark Reynolds, PhD; Senior Director, Gen-Probe
7.2. Mark Chandler, PhD; Chairman and CEO, Biophysical Corporation
7.3. Roberto Hernán, PhD; Head of Business Development, Dominion Pharmakine
7.4. Michael Milburn, PhD; Chief Scientific Officer, Metabolon

Chapter 8
DISCUSSION AND SUMMARY OF CANCER BIOMARKER FINDINGS
8.1. Background
8.2. Studying Cancer Biomarkers
8.3. Important Cancer Biomarkers
8.4. Cancers
  Lung Cancer
  Colorectal Cancer
  Prostate Cancer
  Breast Cancer
  Other Cancers
8.5. Markets

References

Company Index with Web Addresses